

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Strategic Trading Analysis

Based on the detailed PDF report provided, here is the positional trading analysis for **LUPIN.NS**. Note that the dates in the report indicate the data is from **February 2026**.

Step 1: Audit the Data

● Data Present:

- **Price Action:** Daily (3-year), Weekly, and 15-minute candlestick charts with EMA overlays.
- **Trend Indicators:** EMA (20, 50, 200), Supertrend, Bollinger Bands, and MACD.
- **Momentum/Oscillators:** RSI (14), Relative Strength (RS) against benchmark, and Volume analysis.
- **Fundamental Snapshot:** Revenue/Net Income trends, Analyst Estimates, and Valuation scores.
- **Signals:** Specific dates for Golden Cross, Sell signals, and Distribution days.

● Data Missing:

- **Fibonacci Retracement Levels:** While readable from the chart, explicit levels are not drawn to identify confluence with EMAs.
- **Option Chain Data:** No Open Interest (OI) data to confirm resistance/support levels via derivatives.
- **Confidence Level: High.** The report is comprehensive, providing multi-timeframe technicals (Weekly/Daily/Intraday) and fundamental context, allowing for a precise technical assessment.

Step 2: Analyze the Setup

- **Price Structure (Trend):** The stock is in a confirmed **Primary Uptrend** (Weekly/Daily) with price trading above the 50-day and 200-day EMAs. However, the 15-minute chart indicates a **Short-Term Downtrend**, suggesting an ongoing minor correction or consolidation phase.

- **Moving Averages:** The EMAs are stacked bullish (20 > 50 > 200). The price (2173) is hovering just above the 20 EMA (2161) but is showing signs of fatigue.

● Momentum & Volume:

- **Weakness:** The report flags "Weakening Momentum" on the MACD and notes a "Weakening Leader" RS classification.
- **Distribution:** A major red flag is the presence of multiple **Distribution Days** in late January 2026 (Page 18), indicating institutional selling into strength.
- **RSI:** At 53.59, RSI is neutral. It has cooled off from overbought levels but has not yet hit a "value" buy zone (typically 40-45 in uptrends).

● Support/Resistance:

- **Immediate Support:** 2125 (50 EMA) and 2089 (Supertrend Support).
- **Resistance:** 2250 - 2300 (Recent consolidation highs).
- **Confluence:** The current setup shows a stock taking a breather. The 15-minute Sell signal warns against an immediate market-order entry. The risk-to-reward ratio at the current price (CMP) is suboptimal because the stop-loss needs to be below the Supertrend (2089), offering barely a 1:1.5 ratio to the recent highs.

Step 3: Formulate the Recommendation

Verdict: NO (Do not enter at Current Market Price of 2173.70).

Reasoning: While the long-term trend is bullish, the short-term signals (15-min downtrend, distribution days,

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

and weakening MACD) suggest the correction is not yet complete. Buying now risks entering during a "falling knife" scenario with a poor Risk-to-Reward ratio. It is safer to wait for the price to test stronger support levels.

Conditional Plan (Limit Order Strategy):

- **Condition to Buy:** Wait for the price to pull back to the **50-day EMA** zone and demonstrate support (e.g., a bullish hammer candle or 1-hour close above previous high). Alternatively, if price refuses to drop, wait for a high-volume close above 2220 to confirm the correction is over.
- **Entry Price:** INR 2125 - INR 2135 (Buying near the 50 EMA improves R:R significantly).
- **Stop Loss:** INR 2070 (Daily Close). This places the stop below the Supertrend support (2089) and the psychological 2100 level.
- **Take Profit:** INR 2350 (First Target - retest of highs) and INR 2420 (Extended Target based on trend continuation).

Note: This setup offers a potential ~12% upside with a ~2.5% risk, aligning with the "Intermediate-Term" goal.

Candlestick Classification Analysis

Based on the **Candlestick Classification Report (Page 20)** and the **visual chart analysis (Page 21)**, here is my professional assessment of the price action for **LUPIN.NS**.

1. Current Market State: "The Eye of the Storm"

- **Latest Classification: No Control (0)**
- **10-Day Trend Score: 0.00**

Interpretation: As a seasoned trader, a 10-day average score of exactly **0.00** is a critical data point. It indicates that for the last two weeks, the battle between bulls and bears has resulted in a complete stalemate. The market has entered a state of **equilibrium**.

Applying the provided logic:
* **Body Strength:** The recent candles likely have bodies $< 0.5 \text{ ATR}$, indicating a lack of conviction from either side.
* **Wick Analysis:** We are likely seeing candles with wicks on both sides (Spinning Tops or Dojis), signifying intra-day volatility that fails to result in directional progress.
* **Volume:** The volume (Page 21, bottom panel) appears to have tapered off compared to the surge seen in January. Without the "Volume Multiplier" (Step 4), price action remains categorized as "No Control."

2. Chart Analysis (Page 21)

Looking at the **LUPIN.NS - Candlestick Classification Chart**, we can deconstruct the recent sequence:

The January Rally (Green Phase): In early January, we see clear **Buyer Strong Control (+2)** candles (Dark Green). These were characterized by:

- Large bodies ($>1.5 \text{ ATR}$).
- Closing near the high.
- High Volume (Validating the move).

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

The Rejection (Red Phase): Approaching the INR 2250 level, the candles shifted to **Seller Control (-1)** and **Seller Strong Control (-2)**. Note the candle with the long upper wick near the peak-this was a classic "Step 3: Wick Analysis" bearish adjustment, showing sellers defending the high prices.

The Current Pullback (Grey Phase): The far-right side of the chart is dominated by **Grey (No Control)** candles with intermittent **Light Red (Seller Control)** bars.

- The price is drifting lower, but not crashing.
- The absence of **Seller Strong Control (-2)** (Dark Red) in the last few days suggests that while buyers are exhausted, sellers are not aggressive enough to dump the stock. They are simply taking profits.

3. The Logic-Based Prediction

Based on the algorithm provided, here is the forecast for the next immediate moves:

The Bias: Neutral to Slightly Bearish (Correction Mode)

The transition from "Buyer Strong Control" to "No Control" (with a 0.00 score) usually signals a **consolidation pattern** (Flag or Pennant).

Bearish Scenario (Breakdown): Watch for a candle closing below the recent low of this consolidation range.

- *Trigger:* A candle with **Body > 1.0 ATR** closing near the low.
- *Confirmation:* Volume > 1.3x average.
- *Algorithm Consequence:* This would shift the score to -2 (Seller Strong Control), confirming the end of the consolidation and a deeper correction.

Bullish Scenario (Resumption): Since the primary trend (multi-month) is up, this "No Control" period could be a pause before continuation.

- *Trigger:* We need to see a "Green" candle emerge from this grey cluster. specifically a **Buyer Control (+1) or Strong Control (+2)**.
- *Requirements:* Price must close near the high of the day to override the recent selling pressure (Step 2: Close Position Adjustment).

Verdict

Current Action: WAIT / WATCH

The logic is screaming **INDECISION**. The market participants are waiting for a catalyst.* **Do not buy yet:** The "No Control" status means momentum has vanished. Buying now is gambling against the drift.* **Do not short yet:** There is no "Seller Strong Control" on high volume to indicate a trend reversal.

Prediction: Expect 1-3 more days of "No Control" or "Seller Control" (mild downside) as the stock digests the recent run-up. The price will likely test a support level (likely near the 20 EMA seen on other pages) before volume returns. The next significant move will likely be indicated by a return of **High Volume**

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

(Step 4 of your logic)-watch the volume bars closely. If volume spikes on a red candle, the trend breaks. If volume spikes on a green candle, the rally resumes.

News & Analyst Targets

As a stock research analyst, I have compiled the latest information on **Lupin Limited** for the week ending February 7, 2026.

1) Latest News for LUPIN (Week of Feb 1-7, 2026)

- **US FDA Clears Somerset Facility:** In a major positive development, the US FDA completed a Pre-Approval Inspection (PAI) of Lupin's **Somerset, New Jersey** manufacturing facility on **February 1, 2026**. The inspection concluded with **zero 483 observations**, indicating a clean chit for the facility.
- **New Product Launch in US:** On **February 5, 2026**, Lupin announced the launch of **Topiramate Extended-Release Capsules** (generic version of Trokendi XR) in the US market. This drug is used to treat seizures and prevent migraines, addressing a market estimated at ~\$164 million annually.
- **Stock Hits 52-Week High:** Driven by positive FDA news, Lupin's stock price surged early in the week, hitting a new **52-week high of INR 2,249.30 on February 3, 2026**. However, it saw some profit-booking later in the week, closing around INR 2,168.
- **Upcoming Q3 Results:** The company has scheduled a Board Meeting on **February 12, 2026**, to consider and approve the unaudited financial results for the third quarter (Q3 FY26) ending December 31, 2025.
- **Strategic Partnership:** Lupin has entered into a collaboration with **TB Alliance** to advance the development of **Telacebec**, a new treatment for tuberculosis, further strengthening its respiratory and infectious disease portfolio.

2) Brokerage Upgrades & Downgrades

- **MarketsMojo (Downgrade):** On **January 28, 2026**, research firm MarketsMojo downgraded its technical rating on Lupin from "Strong Buy" to "Buy", likely due to valuation concerns after the stock's recent sharp rally.
- **Systematix (Hold):** Recent reports suggest Systematix has maintained a "**Hold**" rating, citing that while revenue growth is steady, valuations are becoming expensive.
- **JPMorgan (Maintain):** JPMorgan has maintained a positive outlook (from late 2025 reports), having raised their target to **INR 2,600** citing strong margin recovery and a robust US pipeline.

3) Other News Impacting LUPIN

- **Sector Trends:** The Nifty Pharma index has been performing well, with the healthcare sector gaining ~3% this week. Lupin has slightly outperformed the broader Sensex, showing resilience in a volatile market.
- **Regulatory Watch (Goa Facility):** While the Somerset news is positive, investors are still monitoring the **Goa facility**, which received **seven observations** from the US FDA in **November 2025**. The resolution of these observations remains a key trigger for the stock in the medium term.

4) Latest Analyst & Brokerage Targets

Below is the summary of the latest available price targets from the analyst community.

Brokerage / Source	Recommendation	Target Price (INR)	Date / Period	Notes
JPMorgan	Overweight	2,600	Nov 2025	Raised target on strong margin beat & US pipeline.

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Brokerage / Source	Recommendation	Target Price (INR)	Date / Period	Notes
FundsIndia	Buy	2,543	Jan 16, 2026	Expects continued growth in US generics.
Consensus Estimate	Buy	2,306	Feb 07, 2026	Average of ~22 analyst reports (Trendlyne).
ICICI Direct	Buy	2,275	Nov 2025	Positive on niche launches in the US.
Geojit BNP Paribas	Buy	2,225	Nov 2025	Maintained buy on steady earnings visibility.
BofA Securities	Neutral	2,030	Nov 2025	Cautious on valuation despite operational improvements.
ICICI Securities	Hold	1,950	Nov 2025	Conservative stance due to regulatory overhangs.

Analyst View: The consensus view is currently **Positive**, with an average upside potential of ~6-7% from current levels (approx. INR 2,168). The primary catalyst to watch next week will be the **Q3 Earnings on Feb 12**, where margins and FDA remediation updates will be in focus.


Stock Detailed Analysis Report

LUPIN.NS

Current Price: ₹2173.70

Generated: 2026-02-07 10:32

LUPIN.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	12.90%	11.08%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	10.81%	2.93%
Net Income	Yes	57.80%	13.71%
ROE	No	-17.62%	-17.62%
EPS	Yes	0.27%	3.32%

LUPIN.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	54.4/100
:	

== RS RATIOS ==:

1M RS:	1.034 [Leader]
3M RS:	1.121 [Leader]
6M RS:	1.169 [Leader]
1Y RS:	0.996 [Neutral]
:	


== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


SIGNAL CRITERIA::

✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	1Y=0.996 (≤ 1.0)
✗ Performance Improving:	Not improving


Relative Strength Analysis: LUPIN.NS vs ^CNXPHARMA
Classification: Weakening Leader
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



LUPIN.NS - EMA Crossover Summary

EMA 20:	2161.70
EMA 50:	2125.55
EMA 200:	2034.72
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-13 00:00:00+05:30
Golden Cross Price:	2052.90

LUPIN.NS EMA Crossover Analysis



LUPIN.NS - Bollinger Bands Summary

Current Price:	2173.70
Upper Band:	2220.23
Middle Band (SMA 20):	2168.67
Lower Band:	2117.11
%B:	0.5488
Band Width:	0.0475
Status:	Upper Half
Signal:	None
Recent Signal 1:	Sell Signal at 2025-11-17 00:00:00+05:30


LUPIN.NS Bollinger Bands (20, 2) Analysis



LUPIN.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	2089.93
Signal Identified On:	2025-11-12


Supertrend Analysis for LUPIN.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




LUPIN.NS - MACD Summary

MACD Line:	14.64
Signal Line:	13.61
Histogram:	1.03
Trend:	Bullish
Momentum:	Weakening
Signal:	None
Divergences Detected:	1
└ Bearish Divergence:	Date: 2026-02-05 00:00:00+05:30, Price: 2218.50

LUPIN.NS Price




LUPIN.NS MACD (12, 26, 9)



LUPIN.NS - Volatility Squeeze Summary

BB Width:	0.0475
ATR:	54.0357
Total Signals:	31
Signal 1:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 2185.90)
Signal 2:	BB Squeeze (Bullish Breakout) at 2026-01-06 00:00:00+05:30 (Price: 2195.20)
Signal 3:	BB Squeeze at 2026-02-03 00:00:00+05:30 (Price: 2185.90)
Signal 4:	BB Squeeze at 2026-02-04 00:00:00+05:30 (Price: 2195.20)
Signal 5:	BB Squeeze at 2026-02-06 00:00:00+05:30 (Price: 2173.70)

LUPIN.NS - Volatility Squeeze Analysis



LUPIN.NS - RSI-Volume Summary

Current RSI:	53.59
Current Volume:	600785
Volume MA 20:	807543
Bullish Divergences:	0
Bearish Divergences:	3
Bearish Div 1:	Date: 2025-04-28 00:00:00+05:30, Price: 2092.39
Bearish Div 2:	Date: 2025-12-22 00:00:00+05:30, Price: 2126.30

LUPIN.NS RSI-Volume Divergence Analysis



LUPIN.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status: 37 Signals Detected

:

2026-01-16 [-]: Distribution Day



2026-01-19 [-]: Distribution Day

2026-01-20 [-]: Distribution Day

2026-01-21 [-]: Distribution Day

2026-01-28 [-]: Distribution Day

LUPIN.NS - Volume Analysis



LUPIN.NS - Candlestick Classification Summary

== CANDLESTICK CLASSIFICATION ==:

Latest Classification: No Control

Recent Trend Score (10-day avg): 0.00

:

Distribution:

No Control: 115


Seller Control: 54

Buyer Control: 52

Seller Strong Control: 4

Buyer Strong Control: 3

LUPIN.NS - Candlestick Classification




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	2025.98	2173.7	2025-12-01
1 Day	UPTREND (Buy)	2089.93	2173.7	2025-11-12
15 Min	DOWNTREND (Sell)	2191.24	2173.7	2026-02-05

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bullish	Strengthening	No Signal

LUPIN.NS - 1 Week (Candlestick + EMAs)



LUPIN.NS - 1 Day (Candlestick + EMAs)



LUPIN.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - LUPIN_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More ▾

Search Stock, IPO, MF A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [LUPIN LTD.](#)

Lupin Ltd.

NSE: LUPIN | BSE: 500257
Lupin Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive In 1 Starfolio Basket

2173.70 -44.80 (-2.02%)
↑ New 52W High in past week

665.8K NSE+BSE Volume
NSE 06 Feb, 2026 3:31 PM (IST)

ABOUT Established in 1968, Lupin is a global pharmaceutical company focused on developing and distributing a diverse range of healthcare products. Its portfolio includes generics, branded generics, complex generics, APIs, biosimilars, and specialty medicin... [Read More](#)

Watchlist Portfolio Alert My Notes **TRADE STOCK**

Board Meeting The next board meeting for Lupin is on 12 Feb 2026 for the purpose of Quarterly Results [See details](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News ▾ Reports Technicals ▾ Shareholding ▾ Deals ▾ Corporate Actions ▾ Alerts About

Durability score **70.0** /100 Valuation Score **42.2** /100 Momentum Score **68.8** /100 Analyst Price Target **2,306** 1Yr Price target upside is 6%

High Financial Strength Mid Valuation Technically Moderately Bullish

Strong Performer, Getting Expensive These stocks are strong in quality and technicals but have medium valuation. At somewhat expensive v... [View Similar](#) Embed DVM

FORECASTER DVM Key Metrics Price Chart Forecaster Financials Technicals Shareholding Deals Documents Corporate actions Company Profile

Check Before You Buy [VIEW FULL CHECKLIST](#)
High rank **18** Positive + **5** Negative **78.3% Pass in checklist**

SWOT Analysis

PE Valuation Check
Right Now Undervalued **128.4%** 1 Year Forward Undervalued **137.1%**
INSIGHT High 5Yr PE Avg of 52.5 may distort upside values.

Lupin Key Metrics

Preset Metrics Preset Metrics ▾

Trendlyne Snapshot - LUPIN_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [A](#)

Search Stock, IPO, MF [India](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [LUPIN LTD.](#)

Lupin Ltd. ⓘ

NSE: LUPIN | BSE: 500257

Strong Performer, Getting Expensive ⓘ In 1 Starfolio Basket

2173.70 -44.80 (-2.02%) ↑ New 52W High in past week

665.8K NSE+BSE Volume
NSE 06 Feb, 2026 3:31 PM (IST)

Download real time STOCK REPORT

Watchlist Portfolio Alert My Notes TRADE STOCK

Board Meeting The next board meeting for Lupin is on 12 Feb 2026 for the purpose of Quarterly Results See details

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Lupin - LUPIN - stock price prediction, stock forecast, target price, analyst ratings from 37 analysts

Lupin has a share price target of Rs 2306, revenue growth forecast of 14.8%, and profit growth estimate of 37.7% for FY26, based on top 37 analyst calls.

Lupin FORECASTER - Analyst Estimates ⓘ

[FORECASTER DASHBOARD →](#)

